Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including soli
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
08:30pm, Monday, 18'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including soli
Atara Biotherapeutics (ATRA) Moves to Strong Buy: Rationale Behind the Upgrade
04:00pm, Monday, 18'th May 2020
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Atara Biotherapeutics (ATRA) Moves to Strong Buy: Rationale Behind the Upgrade
12:00am, Monday, 18'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including soli
Slate Path Capital LP Buys Mylan NV, Ironwood Pharmaceuticals Inc, Pan American Silver Corp, ...
12:00am, Friday, 15'th May 2020Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
08:05pm, Thursday, 14'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
12:00am, Thursday, 14'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transform
Why Atara Biotherapeutics (ATRA) Stock Might be a Great Pick
01:21pm, Wednesday, 13'th May 2020
Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
JP Morgan Maintains Neutral on Atara Biotherapeutics, Raises Price Target to $23
12:00am, Tuesday, 12'th May 2020Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
08:01pm, Monday, 11'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
06:02pm, Monday, 11'th May 2020
Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
Will Atara Biotherapeutics Continue to Surge Higher?
03:25pm, Monday, 11'th May 2020
As of late, it has definitely been a great time to be an investor Atara Biotherapeutics
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
12:00am, Monday, 11'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transform
Edited Transcript of ATRA earnings conference call or presentation 6-May-20 8:30pm GMT
08:12am, Friday, 08'th May 2020
Q1 2020 Atara Biotherapeutics Inc Earnings Call
